With metagenomics, genomics, and other analyses, researchers saw a potential antifungal compound called cyphomycin produced by Streptomyces in an ant in Brazil.
The company intends to use the funding to expand its operations and support sales of its Cyto-Mine single-cell analysis system.
Sphere Fluidics' Cyto-Mine system automates single-cell analysis, sorting, imaging, and dispensing to help speed biopharmaceutical discovery.
Adaptive will use its T-cell receptor screening platform to identify TCRs that can be used to target individual cancer patients' neoantigens.
Aside from its core synthetic biology business, the company has expanded into NGS and is looking to move into drug discovery and DNA data storage.
HitGen will apply its DNA-encoded library design, synthesis, and screening platform to discover novel leads for Bayer research endeavors.
The new division — called Celmatix Biosciences — will focus on women's health indications with high unmet need including reproductive disorders and menopause.
The researchers will not only explore tissue and circulating biomarkers but also the role of the microbiome in predicting benefit from immune checkpoint inhibitors.
The company said it will use the award to further develop its ImmuneProfiler neoantigen prediction technology for personalized cancer medicine.
H3, a subsidiary of Japanese drugmaker Eisai, is developing personalized cancer treatments targeting genomic alterations, including aberrant RNA splicing.
The companies will work together to identify the genetic mutations that cause the rare genetic lysosomal storage disorder alpha mannosidosis.
The partners will evaluate patients' responses to immunotherapeutic drugs, including PD-1 and PDL-1 inhibitors, based on bladder cancer subtypes.
Cofactor's kit will be used to characterize the immune responses generated in reaction to treatment with an investigational personalized cancer vaccine.
TwoXAR's proprietary artificial intelligence technology uses a variety of biomedical data including genomic, proteomic, and clinical data for drug discovery.
In this arm of the trial, 23 percent of patients treated with AKT1 E17K mutations saw their tumors shrink, a better result than those seen in three other trial arms.
During the meeting, researchers presented studies on combination immunotherapies and the efficacy of giving molecularly-informed treatments earlier in the disease continuum.
Screening of disease-linked cell types might bolster drug discovery efforts in schizophrenia, according to a proof-of-concept study.
The new RNA sequencing analysis workflow integrates Roche's RNA-seq library kits with Genialis' automated data processing pipeline for gene expression analyses.
The phenome-wide association study focused on SNPs near potential drug target sites with ties to one or more phenotypes that might impact target suitability.
The agency issued draft guidance on minimal residual disease as a biomarker and finalized another guidance on developing drugs with pan-cancer indications.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.